CAR-T in MM: Best Practices in Patient Selection, Treatment, and Mul…

Icahn School of Medicine at Mount Sinai

A. Rossi

Updates on the Management of Later Relapses of Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

S. Rubinstein

Experts Discuss How They Plan to Use CAR-T in Myeloma After First Re…

MyCancerHaven

R. Vij, A. Abdallah

UChicago Medicine Best of ASCO® 2024: Myeloma

UChicago Medicine Annual Practice Updates in Hematology and Oncology

J. Cooperrider

Real-World Experience With Ide-Cel in R/R MM

Donna Reece

Practical Perspectives on Recent CAR-T FDA Approvals in Myeloma

City of Hope

M. Janakiram

Early Line CAR-Ts in Myeloma - Updates and Future Directions

Krina Patel

BCMA & Beyond: Novel Targets for Immunotherapy in MM

Rush University Medical Center

B. Derman

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

CAR-T vs. Bispecific Antibodies in R/R MM: Insights and Future Direc…

Rush University Medical Center

A. Suvannasankha

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

Samer Al Hadidi

Managing Infectious Complications With Bispecific and CAR-T Therapy …

SOHO Brazil 2024

N. S. Raje

Experts Discuss Current Approaches in Triple Class Refractory MM

MyCancerHaven

R. Vij, J. Zonder, J. Richter

ASCO® 2024 Insights: "Sequencing Immunotherapy for Myeloma"

2024 ASCO® Annual Meeting Insights Hub

S. Parekh

CAR T-Cells in Multiple Myeloma in 2024

Dana-Farber Cancer Institute

A. Sperling

CAR T-Cell Therapies for Pts With R/R Myeloma: Updates From the Real…

Moffitt Cancer Center

D. Hansen

Future of Novel Next Generation Therapy in the Management of R/R MM

Dana-Farber Cancer Institute

P. Richardson

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

2024 ASCO® Annual Meeting Insights Hub

B. Derman

Multiple Myeloma: Experts Discuss How to Choose Between CAR-Ts and B…

MyCancerHaven

R. Vij, N. Nathwani

Multiple Myeloma: What You Need to Know About New FDA Approvals of C…

Moffitt Cancer Center

D. Hansen

Multiple Myeloma: Understanding Your Immune Effector Therapeutic Opt…

Indy Hematology Review

S. Usmani

2024 Updates in MM: The Role of Immunotherapy

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Cohen

How I Treat R/R MM With CAR-T and Bispecific Antibodies

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

C. Cerchione

Triple-Class-Exposed R/R MM: Results From the KarMMa-3 Trial of Ide-…

Insights from 2023 ASH Annual Meeting

K. Patel

Multiple Myeloma: Adverse Effects of CAR-T

Icahn School of Medicine at Mount Sinai

S. Rajeeve